Related Experiment Video
Updated: Oct 6, 2025
Generation and Grafting of Tissue-engineered Vessels in a Mouse Model
Published on: March 18, 2015
Polyurethane-Cardiolipin Nanoparticle-Modified Decellularized Scaffold-Based Vascular Patches for Tissue Engineering
Haomiao Zhu1, Lei Fu1, Lei He1
1Jiangsu Collaborative Innovation Center of Biomedical Functional Materials, National and Local Joint Engineering Research Center of Biomedical Functional Materials, Jiangsu Engineering Research Center for Biomedical Function Materials, School of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China.
This study developed a novel vascular patch using a polyurethane-cardiolipin/polyurethane composite film and a decellularized scaffold. The resulting composite vascular graft (CLVP) demonstrated excellent biocompatibility and maintained blood vessel patency in vivo.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Cardiovascular Engineering
Background:
- Decellularized scaffolds (DCS) are promising for vascular defect repair.
- Cardiovascular diseases necessitate advanced vascular graft materials.
- Polyurethane-based materials offer potential for vascular tissue engineering.
Purpose of the Study:
- To fabricate and evaluate a novel polyurethane-cardiolipin/polyurethane composite film (PU-CL/PU).
- To develop a decellularized scaffold-based vascular patch incorporating the composite film (CLVP).
- To assess the biocompatibility and in vivo performance of the CLVP for vascular defect treatment.
Main Methods:
- Fabrication of PU-CL/PU composite film via nanoparticle cosedimentation.
- Construction of the CLVP by combining PU-CL/PU film with DCS.
- In vitro biocompatibility testing including coagulation, hemolysis, platelet adhesion, and cytotoxicity assays.
- In vivo evaluation of CLVP in a mouse model using B-ultrasound and Doppler spectrum analysis.
Main Results:
- The PU-CL/PU film exhibited enhanced biocompatibility: prolonged coagulation time, reduced hemolysis, and decreased platelet adhesion.
- The composite film showed reduced cytotoxicity and improved endothelial progenitor cell affinity.
- The CLVP successfully maintained blood vessel patency for 30 days post-implantation in mice.
- Significant endothelialization was observed at the surgical site, indicating successful tissue integration.
Conclusions:
- The developed CLVP demonstrates superior biocompatibility and promising in vivo performance.
- The CLVP holds significant potential as a therapeutic option for treating diseased or damaged blood vessels.
- This composite vascular graft represents a viable advancement in cardiovascular tissue engineering.
